Topic: acute myeloid leukemia
Two Swiss pharma giants got some news out of England Tuesday that they weren’t too excited about.
Patients with a specific type of acute myeloid leukemia have their first treatment option with an FDA approval Tuesday.
Pfizer's leukemia drug Mylotarg, pulled off the market in 2010, won backing for a new FDA approval in a Tuesday panel vote.
Novartis got FDA approval today for Rydapt, its new breakthrough treatment for acute myeloid leukemia (AML), which is expected to generate more than $250 million in annual sales in the next few years.
AbbVie and its development partners have big plans for the upcoming American Society of Hematology (ASH) meeting that starts Dec. 3.